- Home
- BIIB vs STM Comparison
BIIB vs STM Comparison
Compare BIIB & STM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- STM
- Stock Information
- Founded
- BIIB 1978
- STM 1987
- Country
- BIIB United States
- STM Netherlands
- Employees
- BIIB N/A
- STM N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- STM Semiconductors
- Sector
- BIIB Health Care
- STM Technology
- Exchange
- BIIB Nasdaq
- STM Nasdaq
- Market Cap
- BIIB 18.8B
- STM 22.3B
- IPO Year
- BIIB 1991
- STM 1994
- Fundamental
- Price
- BIIB $133.99
- STM $32.17
- Analyst Decision
- BIIB Buy
- STM Buy
- Analyst Count
- BIIB 27
- STM 8
- Target Price
- BIIB $188.17
- STM $32.00
- AVG Volume (30 Days)
- BIIB 1.3M
- STM 6.8M
- Earning Date
- BIIB 07-31-2025
- STM 07-24-2025
- Dividend Yield
- BIIB N/A
- STM 0.99%
- EPS Growth
- BIIB 26.39
- STM N/A
- EPS
- BIIB 10.12
- STM 1.18
- Revenue
- BIIB $9,816,400,000.00
- STM $12,321,000,000.00
- Revenue This Year
- BIIB N/A
- STM N/A
- Revenue Next Year
- BIIB N/A
- STM $14.19
- P/E Ratio
- BIIB $13.29
- STM $26.87
- Revenue Growth
- BIIB 1.59
- STM N/A
- 52 Week Low
- BIIB $110.04
- STM $17.25
- 52 Week High
- BIIB $238.00
- STM $43.32
- Technical
- Relative Strength Index (RSI)
- BIIB 56.84
- STM 62.98
- Support Level
- BIIB $129.08
- STM $31.53
- Resistance Level
- BIIB $137.84
- STM $33.14
- Average True Range (ATR)
- BIIB 4.01
- STM 0.61
- MACD
- BIIB 0.57
- STM 0.06
- Stochastic Oscillator
- BIIB 70.81
- STM 79.26
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About STM STMicroelectronics N.V.
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconducteurs in France formed STMicroelectronics in 1987. STMicroelectronics is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. It is an especially prominent chip supplier to the industrial and automotive industries.